23 active not recruiting. 23 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Active not recruiting 23 |
| Phase 2 | 7 | Active not recruiting 7 |
Follow Pt: new trials by email Literature Review of Pt trials Research Report on Pt
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma Antiandrogen Therapy, Biospecimen Collection, Hypofractionated Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Phase 3 | Active not recruiting | Mayo Clinic | 118 | 2024-04-04 | 2026-09-17 |
| Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cisplatin, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 290 | 2023-06-08 | 2026-09-14 |
| Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers Atezolizumab, Bevacizumab, Biospecimen Collection - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 430 | 2023-03-13 | 2026-11-03 |
| Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative Biopsy Procedure, Biospecimen Collection, Computed Tomography - Lung Adenocarcinoma, Lung Adenosquamous Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2022-10-07 | 2026-10-01 |
| Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer Cisplatin, Computed Tomography, Magnetic Resonance Imaging - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 475 | 2022-02-01 | 2026-10-23 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 244 | 2021-10-05 | 2026-11-04 |
| A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma | Phase 3 | Active not recruiting | Children's Oncology Group | 113 | 2021-09-14 | 2026-07-30 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-27 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer Atezolizumab, Biospecimen Collection, Computed Tomography - Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 417 | 2020-08-13 | 2026-10-27 |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial Apalutamide, Biospecimen Collection, Bone Scan - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 586 | 2020-04-16 | 2026-08-17 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 363 | 2019-10-22 | 2026-10-26 |
| De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 384 | 2019-10-09 | 2026-07-02 |
| Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 994 | 2019-08-29 | 2026-10-22 |
| Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 636 | 2019-08-16 | 2026-10-26 |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Biospecimen Collection, Capecitabine, Carboplatin - Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 300 | 2019-06-26 | 2026-08-24 |
| Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer Biospecimen Collection, Carboplatin, Computed Tomography - Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 600 | 2019-04-05 | 2026-10-26 |
| Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial Best Practice, Biospecimen Collection, Computed Tomography - Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 280 | 2018-11-15 | 2026-10-26 |
| Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study Atezolizumab, Bevacizumab, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2018-01-19 | 2026-10-26 |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate - Mantle Cell Lymphoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 689 | 2017-11-27 | 2026-09-14 |
Showing 20 of 23. Sign in to see all of them.
Oropharyngeal Neoplasms (5) · Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Prostatic Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Lymphoma, Large B-Cell, Diffuse (2) · Mouth Neoplasms (2) · Nasopharyngeal Carcinoma (2) · Adenocarcinoma of Lung (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Epstein-Barr Virus Infections (1)
National Cancer Institute (NCI) (14) · NRG Oncology (5) · ECOG-ACRIN Cancer Research Group (2) · Children's Oncology Group (1) · Mayo Clinic (1)
United States (23) · Canada (10) · Puerto Rico (4) · Australia (3) · Hong Kong (2) · Ireland (2) · Saudi Arabia (2) · China (1) · Guam (1) · Singapore (1) · Switzerland (1) · Taiwan (1)
Aarti Bhatia (1) · Alex F Herrera (1) · Carlos E. Vargas, MD (1) · Christine M Bestvina (1) · David J Sher (1) · Elizabeth A Brem (1) · Hossein Borghaei (1) · Jamie E Chaft (1) · Janice Mehnert (1) · Jeremy S Abramson (1) · Lisa G Roth (1) · Megan E Daly (1) · Nabil F Saba (1) · Nancy Y Lee (1)
PMID 33288485, PMID 34634256, PMID 34686472, PMID 35613998, PMID 36416836, PMID 36485104, PMID 37505794, PMID 38421243, PMID 38945791, PMID 39413375, PMID 39938471, PMID 41005671, PMID 41512237, PMID 41911908, PMID 42224490, PMID 42525921, PMID 42526889, PMID 42577949, PMID 42660130, PMID 42702214
U10CA180820 (7), U10CA180868 (7), U10CA180888 (4), U10CA180821 (2), U10CA180886 (2), U10CA021661 (1), U10CA180822 (1)